Author

M. Mazan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

T. Rzymski· 2 shared A. Benoit· 1 shared A. Emond· 1 shared A. Galan· 1 shared A. Pierce· 1 shared B. Brunt· 1 shared B. Veo· 1 shared C. A. Piccirillo· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

T. Rzymski

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Transcriptional Regulation of Protein Synthesis by Mediator Kinase in MYC-driven Medulloblastoma

D. Wang, C. Ritz, A. Pierce, B. Brunt, Y. Luo, N. Dahl, S. Venkataraman, E. Danis, K. Kus, M. Mazan, T. Rzymski, B. Veo, R. Vibhakar

This study identifies CDK8 as a critical dependence in MYC-driven medulloblastoma, showing its role in regulating transcription and translation through mechanisms involving ribosome biogenesis and 4EBP1 phosphorylation.

bioRxiv · Mar 8, 2024 · PreprintCancer Biology

The MNK1/2-eIF4E axis contributes to phenotype switching, melanoma progression, and resistance to immunotherapy.

F. Huang, C. Goncalves, M. Bartish, J. Remy-Sarrazin, Q. Guo, A. Emond, W. Yang, D. Plourde, J. Su, M. G. Gimeno, Y. Zhan, M. Attias, A. Galan, T. rzymski, M. Mazan, , S. del Rincon

This study identifies the MNK1/2-eIF4E axis as a driver of melanoma phenotype switching, progression, and immunotherapy resistance, with potential therapeutic targeting.

bioRxiv · May 29, 2020Cancer Biology